GGrantIndex
← Leaderboards

Gautam Sudhir Ghatnekar

Xequel Bio, Inc.

$7,871,466
Attributed
$7,871,466
Total exposure
10
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.2M · FY200720
$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20

Funding mix

By agency

NIH$7,871,466 · 10

By mechanism

R44$4,234,174 · 2
R43$1,376,080 · 6
R42$1,261,212 · 1
SB1$1,000,000 · 1

Top collaborators

No co-investigators on record.

Most similar at Xequel Bio, Inc.

Same institution · by research overlap

Others in their field

Top investigators on “Inflammation

Research focus

InflammationInjuryBasePeptidesSafetyHealingCellsSmall Business Innovation Research GrantConnexin 43Wound HealingBiomedical EngineeringDesignConnexinsWoundImmuneCicatrixSignal TransductionResponseCostChronicExtravasationProteinsClinical TrialsHealed

Grant awards (17)

Improving marginal allograft outcomes through cell junction stabilization in transplantation$300,000
R44 · FY2020 · DK · contact PI
Novel small molecule HSP90 inhibitor for the management of atopic dermatitis$252,131
R43 · FY2020 · AR · contact PI
Evaluation of a Novel Connexin-Based Peptide in the Treatment of Combined Ionizing Radiation and Thermal Burn Injury$300,000
R43 · FY2019 · AI · contact PI
Evaluation of a Novel Connexin-Based Peptide for the Treatment of Diabetic Wounds$147,249
SB1 · FY2018 · DK · contact PI
Evaluation of a Novel Connexin-Based Peptide for the Treatment of Diabetic Wounds$852,751
SB1 · FY2017 · DK · contact PI
Evaluation of a Connexin-based Peptide for the Treatment of Age-Related Macular Degeneration$225,000
R43 · FY2017 · EY · contact PI
Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds$997,264
R44 · FY2016 · DK · contact PI
Stabilization of gap/tight junctions to ameliorate brain death induced endothelial cell injury$225,000
R43 · FY2016 · HL · contact PI
Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds$996,533
R44 · FY2015 · DK · contact PI
Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds$999,289
R44 · FY2014 · DK · contact PI
Development of a novel connexin-based peptide for the treatment of corneal injury$232,760
R43 · FY2012 · EY · contact PI
Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds$323,674
R44 · FY2011 · DK · contact PI
Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds$300,000
R44 · FY2011 · DK · contact PI
Restoration of Skin Structure and Function Post-Wounding$631,997
R42 · FY2010 · AR · contact PI
Evaluation Of A Novel Connexin-Based Peptide For The Treatment Of Diabetic Wounds$317,414
R44 · FY2010 · DK · contact PI
Restoration of Skin Structure and Function Post-Wounding$629,215
R42 · FY2009 · AR · contact PI
Evaluation of a novel connexin-based peptide for the treatment of diabetic wounds$141,189
R43 · FY2007 · DK · contact PI